Interleukin 10 production correlates with pathology in human Leishmania donovani infections
about
Immunoregulation in human American leishmaniasis: balancing pathology and protectionProtection and pathology during parasite infection: IL-10 strikes the balanceB7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infectionsAbortive T follicular helper development is associated with a defective humoral response in Leishmania infantum-infected macaquesImmunotherapy for visceral leishmaniasis: ability of factors produced during anti-leishmania responses of skin test positive adults to inhibit peripheral blood mononuclear cell activities associated with visceral leishmaniasisRole of CD8+ T cells in endogenous interleukin-10 secretion associated with visceral leishmaniasisImmunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccinesDifferential decline in Leishmania membrane antigen-specific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapyDistribution of IgG subclasses in antimonial unresponsive Indian kala-azar patientsCoating doxorubicin-loaded nanocapsules with alginate enhances therapeutic efficacy against Leishmania in hamsters by inducing Th1-type immune responsesA curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapyTherapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c miceImipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infectionCytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasisCharacterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasisHuman and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family.A network map of Interleukin-10 signaling pathwayA recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice.A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis.Virulence of Leishmania infantum is expressed as a clonal and dominant phenotype in experimental infections.Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral LeishmaniasisMacrophage and T-cell gene expression in a model of early infection with the protozoan Leishmania chagasi.Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasisCytokine profiles amongst Sudanese patients with visceral leishmaniasis and malaria co-infections.Immunologic indicators of clinical progression during canine Leishmania infantum infectionAlcoholic Fractions F5 and F6 from Withania somnifera Leaves Show a Potent Antileishmanial and Immunomodulatory Activities to Control Experimental Visceral Leishmaniasis.Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccineCutaneous Manifestations of Human and Murine LeishmaniasisImmune regulation during chronic visceral leishmaniasis.Clinical and experimental advances in treatment of visceral leishmaniasis.Control of Leishmania infantum infection is associated with CD8(+) and gamma interferon- and interleukin-5-producing CD4(+) antigen-specific T cells.Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection.Characterization of a Leishmania tropica antigen that detects immune responses in Desert Storm viscerotropic leishmaniasis patientsImmunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.Type 1/Type 2 immunity in infectious diseases.Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.Progressive visceral leishmaniasis is driven by dominant parasite-induced STAT6 activation and STAT6-dependent host arginase 1 expression.Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation.Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease
P2860
Q26850280-705041A4-820B-4482-9DE1-8EDF9880B8EEQ27005837-C40EA545-28CE-46B4-B6B8-CB96CC2826F8Q27317015-3C10DC6F-CB42-48BB-99AF-ABD6111A2824Q27326637-5616D6DE-CBC9-4856-8EB2-9B1F6C21CB29Q28137699-0DB7743E-E601-4A26-BB98-BD31DB8CC673Q28139641-9E8BCCBF-E4D1-46E1-92A7-46616E73E997Q28273639-040FA7AC-D37E-4506-AED9-258F83362E08Q28343709-1C93A61A-1BB8-43F9-9045-71B7B8591633Q28369347-24E95B8A-5151-4320-8227-2DA914F857C8Q28383050-D6F986D9-8227-4790-8751-C27C54163C7DQ28474921-43FB7387-7CC4-46C7-AA72-147AC6539B1DQ28477398-9039B0F2-BF48-476A-977E-9DE34D27C862Q28484622-361FA829-0815-4294-8AD5-94208B8EB79BQ28485121-156A3922-5061-4945-A8B3-BB1AE44A8CA2Q28539119-A8FCF2A5-1E74-4346-859E-49F3E3D11832Q28585935-889B9FF8-5D97-4024-ABDC-3FD380B63F81Q28603589-0386FA94-4925-4507-8175-4E98E07D0C5AQ30452825-9920F5D9-BBDF-4F0A-84A3-90DAD0DB6F3CQ30833358-8082BC3E-01BD-4DD6-8F45-3A96ACC01515Q31029820-0672E2F5-7C8E-47A4-8010-6AA438986C85Q31060208-93B46F6B-9722-4D1A-8A2B-C66AC1CB0633Q33346267-7D7536D0-864B-4B6B-9493-466E20B80AB7Q33559747-DE922340-C64E-45AB-A3E2-61F6166804B1Q33624814-BD12B5E9-03C3-4496-989F-E1982BD6989FQ33627078-1B51952A-1E3D-4C6B-9A96-283740D74ED5Q33665654-0D6AE55B-44F2-4A81-9C3A-5B19B2576987Q33817531-47DCF887-2838-42D2-8F6F-2BAA6C9D3A35Q33839048-C09BC7F5-8A50-478C-A412-404B92622F5FQ33881718-203B339B-DFE1-4386-9093-67B7C894D5C6Q33982648-694318C7-CE7B-4253-BBA5-89D321B9D4FCQ34002287-A0E3BC96-AB96-4170-AA0D-BA01303DAFB4Q34003750-A4A3D94C-9F95-4B02-921D-F92C140CA11FQ34021428-11503F29-8CD8-44B3-9692-6AB35E36A2D4Q34054948-C7A8B89D-3AB9-45FF-95F5-C62D17D51EBBQ34105379-155925BD-BDA3-42A8-B853-6242C785E739Q34128082-6A955675-D0CE-491D-998D-0C0C89023AB5Q34139938-055958DB-03E9-4F7F-8F5D-4C8B8EA8C917Q34149280-D30D979A-8E70-4A9D-9894-C7C22CF0CDA4Q34181985-5EB6A877-D04B-429A-9AA1-A684065877CCQ34262223-214FEF7E-66B5-4C67-9B23-D5476E568423
P2860
Interleukin 10 production correlates with pathology in human Leishmania donovani infections
description
1993 nî lūn-bûn
@nan
1993 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Interleukin 10 production corr ...... Leishmania donovani infections
@ast
Interleukin 10 production corr ...... Leishmania donovani infections
@en
Interleukin 10 production corr ...... Leishmania donovani infections
@nl
type
label
Interleukin 10 production corr ...... Leishmania donovani infections
@ast
Interleukin 10 production corr ...... Leishmania donovani infections
@en
Interleukin 10 production corr ...... Leishmania donovani infections
@nl
prefLabel
Interleukin 10 production corr ...... Leishmania donovani infections
@ast
Interleukin 10 production corr ...... Leishmania donovani infections
@en
Interleukin 10 production corr ...... Leishmania donovani infections
@nl
P2093
P2860
P3181
P356
P1476
Interleukin 10 production corr ...... Leishmania donovani infections
@en
P2093
A M el-Hassan
F A Hashim
H W Ghalib
M R Piuvezam
Y A Skeiky
P2860
P3181
P356
10.1172/JCI116570
P407
P577
1993-07-01T00:00:00Z